Trinity Biotech (NASDAQ:TRIB) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Trinity Biotech (NASDAQ:TRIBGet Rating) in a report published on Monday morning. The firm issued a buy rating on the stock.

Separately, TheStreet cut Trinity Biotech from a c- rating to a d- rating in a research note on Monday, December 20th.

TRIB stock opened at $1.14 on Monday. Trinity Biotech has a 1-year low of $0.86 and a 1-year high of $4.01. The business has a fifty day moving average price of $1.07 and a 200-day moving average price of $1.52. The stock has a market capitalization of $23.83 million, a P/E ratio of -7.13 and a beta of 1.55.

Institutional investors and hedge funds have recently modified their holdings of the stock. Hunter Associates Investment Management LLC grew its holdings in shares of Trinity Biotech by 2.0% in the third quarter. Hunter Associates Investment Management LLC now owns 2,095,900 shares of the company’s stock worth $4,527,000 after acquiring an additional 40,200 shares during the period. Wealthsource Partners LLC bought a new stake in shares of Trinity Biotech in the third quarter worth $65,000. LPL Financial LLC grew its holdings in shares of Trinity Biotech by 48.3% in the third quarter. LPL Financial LLC now owns 89,073 shares of the company’s stock worth $192,000 after acquiring an additional 29,000 shares during the period. Millennium Management LLC bought a new stake in shares of Trinity Biotech in the third quarter worth $139,000. Finally, Morgan Stanley grew its holdings in shares of Trinity Biotech by 40.0% in the third quarter. Morgan Stanley now owns 20,765 shares of the company’s stock worth $45,000 after acquiring an additional 5,932 shares during the period. 27.83% of the stock is owned by institutional investors.

Trinity Biotech Company Profile (Get Rating)

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World geographical segments. The company was founded by Ronan O’Caoimh and Denis R.

See Also

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.